National Health (Listed drugs on F1 or F2) Amendment Determination 2013 (No. 2) (No. PB 19 of 2013) (Cth)

Case

PB 19 of 2013

National Health (Listed drugs on F1 or F2) Amendment Determination 2013 (No. 2)1

National Health Act 1953

I, ADRIANA PLATONA, Assistant Secretary, Pharmaceutical Evaluation Branch, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the


Minister for Health, make this determination under subsection 85AB(1) of the National Health Act 1953.

Dated          27               March   2013

ADRIANA PLATONA

Assistant Secretary

Pharmaceutical Evaluation Branch

Pharmaceutical Benefits Division

Department of Health and Ageing

Part 1         Preliminary

  1. Name of Determination

(1)   This Determination is the National Health (Listed drugs on F1 or F2) Amendment Determination 2013 (No. 2).

(2)   This Determination may also be cited as PB 19 of 2013.

  1. Commencement

This Determination commences on 1 April 2013.

  1. Amendment of National Health (Listed drugs on F1 or F2) Determination 2010

Schedule 1 amends the National Health (Listed drugs on F1 or F2) Determination 2010 (PB 93 of 2010).

Schedule 1             Amendments

(Section 3)

[1]     Schedule 1, after item dealing with Bivalirudin

Insert

Boceprevir

[2]     Schedule 1, after item dealing with Calcium

Omit

Candesartan

[3]     Schedule 1, after item dealing with Desmopressin

Omit

Desvenlafaxine

[4]     Schedule 1, after item dealing with Domperidone

Omit

Donepezil

[5]     Schedule 1, after item dealing with Doxorubicin, peglyated liposomal

Omit

Duloxetine

[6]     Schedule 1, after item dealing with Epoprostenol

Omit

Eprosartan

[7]     Schedule 1, after item dealing with Interferon beta-1a

Omit

Interferon Beta-1b

[8]     Schedule 1, after item dealing with Interferon gamma-1b

Omit

Irbesartan

[9]     Schedule 1, after item dealing with Lithium

Omit

Losartan

[10]   Schedule 1, after item dealing with Ofloxacin

Omit

Olmesartan

[11]   Schedule 1, after item dealing with Rosiglitazone

Insert

Rotigotine

[12]   Schedule 1, after item dealing with Tadalafil

Insert

Telaprevir

[13]   Schedule 1, after item dealing with Telbivudine

Omit

Telmisartan

[14]   Schedule 1, after item dealing with Triptorelin

Omit

Tropisetron

[15]   Schedule 1, after item dealing with Valine with carbohydrate

Omit

Valsartan

[16]   Schedule 2, after item dealing with Calcitriol

Insert

Candesartan

[17]   Schedule 2, after item dealing with Desferrioxamine

Insert

Desvenlafaxine

[18]   Schedule 2, after item dealing with Docetaxel

Insert

Donepezil

[19]   Schedule 2, after item dealing with Doxycycline

Insert

Duloxetine

[20]   Schedule 2, after item dealing with Epirubicin

Insert

Eprosartan

[21]   Schedule 2, after item dealing with Indomethacin

Insert

Interferon beta-1b

[22]   Schedule 2, after item dealing with Ipratropium

Insert

Irbesartan

Irbesartan with Hydrochlorothiazide

[23]   Schedule 2, after item dealing with Loperamide

Insert

Losartan

[24]   Schedule 2, after item dealing with Olanzapine

Insert

Olmesartan

[25]   Schedule 2, after item dealing with Tamoxifen

Insert

Telmisartan

[26]   Schedule 2, after item dealing with Trimethoprim with sulfamethoxazole 

Insert

Tropisetron

[27]   Schedule 2, after item dealing with Valproic acid

Insert

Valsartan

Note

1.       All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003. See

Actions
Download as PDF Download as Word Document


Cases Citing This Decision

0

Cases Cited

0

Statutory Material Cited

0